September 30, 2020 Collaboration and continuous optimization: Cornerstones of our strategy
At Rentschler Biopharma, collaboration through our partner network as well as continuous optimization of our business processes, are both strong cornerstones of our strategy. Both of these aspects have been elaborated on, in the latest issue of the Pharma's Almanac magazine.
Our CEO Frank Mathias and Peter Soelkner, Managing Director Vetter Pharma, share insights on our strategic collaboration aimed at simplifying complexities in drug development. They address our commitment to simplifying processes, reducing complexity, and optimizing time-to-market while continuing to deliver on our high-quality standards and sustainably support our clients' needs. To read the entire article, please follow this
In a second feature, Wolfram Schulze, our Vice President Information Systems, Organization & Digital Transformation and Head of Infection Prevention Task Force joins industry experts in the COVID-19 Roundtable. A continuous optimization of operational fitness has always been an integral part of Rentschler Biopharma's strategy. We have been closely monitoring and improving our processes, business continuity and digital maturity, even before the outbreak of the COVID-19 pandemic. Wolfram Schulze elaborates on our response and long-term strategy in light of the experiences endured as a result of the COVID-19 pandemic. For more details, please follow this.
Rentschler Biopharma SE
Dr. Cora Kaiser
Senior Director Corporate Communication